Semaglutide
GLP-1 receptor agonist for metabolic research and weight regulation.
Full titration: wks 1–4 @ 0.25 mg, wks 5–8 @ 0.5 mg, wks 9–11 @ 1 mg
Key Benefits
activates receptors in the pancreas, brain, and gut simultaneously for a coordinated multi-organ metabolic response
reduces hunger signals in the hypothalamus, leading to 10–15% body weight reduction in clinical trials
stimulates insulin release in response to meals while suppressing glucagon, improving blood sugar control
LEADER trial demonstrated a 26% reduction in cardiovascular death, making it a key compound for cardiometabolic studies
Recommended Injection Sites
Optimal injection locations for Semaglutide based on its route (Subcutaneous injection) and pharmacokinetic profile.
Tap a glowing zone on the body map to highlight the matching site card — or tap a card to activate the zone.
Tap a zone to inject
FDA-approved clinical injection site for semaglutide. Largest SubQ depot; most consistent absorption for weekly dosing.
Second preferred site per clinical guidelines. Slightly slower Cmax but equivalent AUC over weekly dosing interval.
Third approved site per Ozempic/Wegovy prescribing information. Requires assistance for consistent placement.
Rotate weekly injection site systematically — abdomen → thigh → upper arm. Never inject the same exact spot twice in a row. Weekly rotation reduces nodule formation.
- IV administration
- Intramuscular injection (alters pharmacokinetics)
- Navel or waistband area
- Injection into skin folds with active lipodystrophy
Active Signaling Pathway
Semaglutide activates GLP-1 receptors simultaneously in the hypothalamus (appetite suppression), gut (gastric emptying), and pancreas (insulin secretion), creating a coordinated multi-organ metabolic response.
Recommended Stacks
Semaglutide is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
Metabolic Reset & Weight Research
The most clinically validated weight-loss stack available — built around the world's most studied peptides.
GLP-1 Starter Protocol
The ideal entry point for GLP-1 research — gentle titration with metabolic support.
Aesthetic Fat Loss Protocol
Targeted lipolysis + systemic fat metabolism + GLP-1 appetite control for comprehensive body recomposition.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 15mg vial — and when to plan your next order.
Actual duration may vary based on your specific protocol. Always consult your research guidelines for precise dosing schedules.
Scientific Background
Mechanism of Action
Semaglutide is a 94% homologous analog of human GLP-1 with a C18 fatty diacid chain attached via a linker to lysine at position 26. This modification enables albumin binding, extending the half-life to ~7 days. It activates GLP-1 receptors in the pancreas (insulin secretion), hypothalamus (appetite suppression), and gut (gastric emptying delay), creating a multi-organ metabolic effect.
Clinical Context
Semaglutide is one of the most extensively studied peptides in modern medicine, with over 40,000 patients enrolled in its clinical trial program. Its weekly dosing schedule and robust efficacy data make it a gold standard reference compound for GLP-1 receptor agonist research. The 2.4 mg/week dose (Wegovy) is FDA-approved for chronic weight management.
Research Highlights
- SUSTAIN and STEP trial programs demonstrated 10–15% body weight reduction at 1 mg/week and up to 15% at 2.4 mg/week
- LEADER trial showed 26% reduction in cardiovascular death in T2D patients with established CVD
- Emerging research shows GLP-1 receptor expression in the brain — semaglutide may reduce neuroinflammation and have neuroprotective effects
- 2023 SELECT trial: 20% reduction in major adverse cardiovascular events in non-diabetic obese patients
Storage & Reconstitution
Research protocols typically use a dose-escalation schedule over 4–16 weeks. Long half-life allows weekly dosing.